Due to its heterogeneity, lack of prognostic markers, tumor-escape mechanisms and frequent relapse upon surgical intervention, treatment of hepatocellular carcinoma (HCC) remains challenging. In this issue of Clinical Cancer Research, Groß and colleagues characterize a rodent model, which might help identify novel drugs for combinatorial sorafenib-based therapies for HCC.